Fariba Raygan1, Zohreh Rezavandi1, Sahar Dadkhah Tehrani2, Alireza Farrokhian1, Zatollah Asemi3. 1. Department of Cardiology, School of Medicine, Kashan University of Medical Sciences, Kashan, Iran. 2. Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, Iran. 3. Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, Iran. asemi_r@yahoo.com.
Abstract
BACKGROUND: Limited data are available indicating the effects of coenzyme Q10 (CoQ10) supplementation on metabolic status of patients with metabolic syndrome (MetS). PURPOSE: The present study was conducted to determine the effects of CoQ10 administration on glucose homeostasis parameters, lipid profiles, biomarkers of inflammation and oxidative stress among patients with MetS. METHODS: This randomized, double-blind, placebo-controlled trial was performed among 60 overweight or obese and type 2 diabetes mellitus patients with coronary heart disease aged 40-85 years old. Participants were randomly allocated into two groups. Group A (n = 30) received 100 mg CoQ10 supplements and group B (n = 30) received placebo for 8 weeks. Fasting blood samples were taken at the beginning of the study and after 8-week intervention to quantify glucose homeostasis parameters, lipid profiles and biomarkers of inflammation and oxidative stress. RESULTS: Compared with the placebo, CoQ10 supplementation resulted in a significant reduction in serum insulin levels (-2.1 ± 7.1 vs. +4.1 ± 7.8 µIU/mL, P = 0.002) and homeostasis model of assessment-insulin resistance (-0.7 ± 2.1 vs. +1.0 ± 2.0, P = 0.002) and homeostatic model assessment-beta cell function (-5.9 ± 22.2 vs. +15.9 ± 34.0, P = 0.005). In addition, patients who received CoQ10 supplements had a significant increase in plasma total antioxidant capacity (TAC) concentrations (+26.0 ± 105.0 vs. -162.2 ± 361.8 mmol/L, P = 0.008) compared with the placebo group. However, after adjustment for the baseline levels, age and baseline BMI, the effect on TAC levels (P = 0.08) disappeared. Additionally, compared with the placebo group, a significant positive trends in plasma glutathione (P = 0.06) and a significant reduction in malondialdehyde (P = 0.08) were seen among patients who received CoQ10 supplement. We did not observe any significant changes in fasting plasma glucose, lipid concentrations and inflammatory markers. CONCLUSIONS: Overall, daily intake of 100 mg CoQ10 supplements among patients with MetS for 8 weeks had beneficial effects on serum insulin levels, HOMA-IR, HOMA-B and plasma TAC concentrations. CLINICAL TRIAL REGISTRATION NUMBER: www.irct.ir : IRCT201502245623N35.
RCT Entities:
BACKGROUND: Limited data are available indicating the effects of coenzyme Q10 (CoQ10) supplementation on metabolic status of patients with metabolic syndrome (MetS). PURPOSE: The present study was conducted to determine the effects of CoQ10 administration on glucose homeostasis parameters, lipid profiles, biomarkers of inflammation and oxidative stress among patients with MetS. METHODS: This randomized, double-blind, placebo-controlled trial was performed among 60 overweight or obese and type 2 diabetes mellituspatients with coronary heart disease aged 40-85 years old. Participants were randomly allocated into two groups. Group A (n = 30) received 100 mg CoQ10 supplements and group B (n = 30) received placebo for 8 weeks. Fasting blood samples were taken at the beginning of the study and after 8-week intervention to quantify glucose homeostasis parameters, lipid profiles and biomarkers of inflammation and oxidative stress. RESULTS: Compared with the placebo, CoQ10 supplementation resulted in a significant reduction in serum insulin levels (-2.1 ± 7.1 vs. +4.1 ± 7.8 µIU/mL, P = 0.002) and homeostasis model of assessment-insulin resistance (-0.7 ± 2.1 vs. +1.0 ± 2.0, P = 0.002) and homeostatic model assessment-beta cell function (-5.9 ± 22.2 vs. +15.9 ± 34.0, P = 0.005). In addition, patients who received CoQ10 supplements had a significant increase in plasma total antioxidant capacity (TAC) concentrations (+26.0 ± 105.0 vs. -162.2 ± 361.8 mmol/L, P = 0.008) compared with the placebo group. However, after adjustment for the baseline levels, age and baseline BMI, the effect on TAC levels (P = 0.08) disappeared. Additionally, compared with the placebo group, a significant positive trends in plasma glutathione (P = 0.06) and a significant reduction in malondialdehyde (P = 0.08) were seen among patients who received CoQ10 supplement. We did not observe any significant changes in fasting plasma glucose, lipid concentrations and inflammatory markers. CONCLUSIONS: Overall, daily intake of 100 mg CoQ10 supplements among patients with MetS for 8 weeks had beneficial effects on serum insulin levels, HOMA-IR, HOMA-B and plasma TAC concentrations. CLINICAL TRIAL REGISTRATION NUMBER: www.irct.ir : IRCT201502245623N35.
Authors: Juan Garrido-Maraver; Mario D Cordero; Manuel Oropesa-Ávila; Alejandro Fernández Vega; Mario de la Mata; Ana Delgado Pavón; Manuel de Miguel; Carmen Pérez Calero; Marina Villanueva Paz; David Cotán; José A Sánchez-Alcázar Journal: Mol Syndromol Date: 2014-07
Authors: Javier Díaz-Castro; Rafael Guisado; Naroa Kajarabille; Carmen García; Isabel M Guisado; Carlos de Teresa; Julio J Ochoa Journal: Eur J Nutr Date: 2011-10-12 Impact factor: 5.614
Authors: Antonio Mancini; Domenico Milardi; Antonio Bianchi; Roberto Festa; Andrea Silvestrini; Laura De Marinis; Alfredo Pontecorvi; Elisabetta Meucci Journal: Arch Androl Date: 2007 Jan-Feb
Authors: Roland Stocker; David E James; Daniel J Fazakerley; Rima Chaudhuri; Pengyi Yang; Ghassan J Maghzal; Kristen C Thomas; James R Krycer; Sean J Humphrey; Benjamin L Parker; Kelsey H Fisher-Wellman; Christopher C Meoli; Nolan J Hoffman; Ciana Diskin; James G Burchfield; Mark J Cowley; Warren Kaplan; Zora Modrusan; Ganesh Kolumam; Jean Yh Yang; Daniel L Chen; Dorit Samocha-Bonet; Jerry R Greenfield; Kyle L Hoehn Journal: Elife Date: 2018-02-06 Impact factor: 8.140